Literature DB >> 25456276

Dysfunction of phospholipase Cγ in immune disorders and cancer.

Hans Koss1, Tom D Bunney2, Sam Behjati3, Matilda Katan4.   

Abstract

The surge in genetic and genomic investigations over the past 5 years has resulted in many discoveries of causative variants relevant to disease pathophysiology. Although phospholipase C (PLC) enzymes have long been recognized as important components in intracellular signal transmission, it is only recently that this approach highlighted their role in disease development through gain-of-function mutations. In this review we describe the new findings that link the PLCγ family to immune disorders and cancer, and illustrate further efforts to elucidate the molecular mechanisms that underpin their dysfunction.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer; deregulation of signaling; disease-linked mutations; immune disorders; phospholipase C

Mesh:

Substances:

Year:  2014        PMID: 25456276     DOI: 10.1016/j.tibs.2014.09.004

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  50 in total

1.  Fluorogenic XY-69 in Lipid Vesicles for Measuring Activity of Phospholipase C Isozymes.

Authors:  Adam J Carr; Edhriz Siraliev-Perez; Weigang Huang; John Sondek; Qisheng Zhang
Journal:  Methods Mol Biol       Date:  2021

2.  PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.

Authors:  D Jones; J A Woyach; W Zhao; S Caruthers; H Tu; J Coleman; J C Byrd; A J Johnson; G Lozanski
Journal:  Leukemia       Date:  2017-04-03       Impact factor: 11.528

Review 3.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

4.  Integrated molecular analysis of adult T cell leukemia/lymphoma.

Authors:  Keisuke Kataoka; Yasunobu Nagata; Akira Kitanaka; Yuichi Shiraishi; Teppei Shimamura; Jun-Ichirou Yasunaga; Yasushi Totoki; Kenichi Chiba; Aiko Sato-Otsubo; Genta Nagae; Ryohei Ishii; Satsuki Muto; Shinichi Kotani; Yosaku Watatani; June Takeda; Masashi Sanada; Hiroko Tanaka; Hiromichi Suzuki; Yusuke Sato; Yusuke Shiozawa; Tetsuichi Yoshizato; Kenichi Yoshida; Hideki Makishima; Masako Iwanaga; Guangyong Ma; Kisato Nosaka; Masakatsu Hishizawa; Hidehiro Itonaga; Yoshitaka Imaizumi; Wataru Munakata; Hideaki Ogasawara; Toshitaka Sato; Ken Sasai; Kenzo Muramoto; Marina Penova; Takahisa Kawaguchi; Hiromi Nakamura; Natsuko Hama; Kotaro Shide; Yoko Kubuki; Tomonori Hidaka; Takuro Kameda; Tsuyoshi Nakamaki; Ken Ishiyama; Shuichi Miyawaki; Sung-Soo Yoon; Kensei Tobinai; Yasushi Miyazaki; Akifumi Takaori-Kondo; Fumihiko Matsuda; Kengo Takeuchi; Osamu Nureki; Hiroyuki Aburatani; Toshiki Watanabe; Tatsuhiro Shibata; Masao Matsuoka; Satoru Miyano; Kazuya Shimoda; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-10-05       Impact factor: 38.330

5.  Phospholipase Cγ1 (PLCγ1) Controls Osteoclast Numbers via Colony-stimulating Factor 1 (CSF-1)-dependent Diacylglycerol/β-Catenin/CyclinD1 Pathway.

Authors:  Zhengfeng Yang; Seokho Kim; Sahil Mahajan; Ali Zamani; Roberta Faccio
Journal:  J Biol Chem       Date:  2016-12-09       Impact factor: 5.157

Review 6.  Ocular Manifestations of Inherited Phospholipase-Cγ2-Associated Antibody Deficiency and Immune Dysregulation.

Authors:  Antonio Di Zazzo; Maryam Tahvildari; George J Florakis; Reza Dana
Journal:  Cornea       Date:  2016-12       Impact factor: 2.651

7.  Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer.

Authors:  Wenqiang Song; Laura C Kim; Wei Han; Yuan Hou; Deanna N Edwards; Shan Wang; Timothy S Blackwell; Feixiong Cheng; Dana M Brantley-Sieders; Jin Chen
Journal:  Mol Cancer Res       Date:  2020-08-04       Impact factor: 5.852

8.  Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.

Authors:  Martin Wist; Laura Meier; Orit Gutman; Jennifer Haas; Sascha Endres; Yuan Zhou; Reinhild Rösler; Sebastian Wiese; Stephan Stilgenbauer; Elias Hobeika; Yoav I Henis; Peter Gierschik; Claudia Walliser
Journal:  J Biol Chem       Date:  2020-03-17       Impact factor: 5.157

9.  FGFR1 Is Critical for RBL2 Loss-Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer.

Authors:  Dong-Wook Kim; Kwon-Sik Park; Kee-Beom Kim; Youngchul Kim; Christopher J Rivard
Journal:  Cancer Res       Date:  2020-09-24       Impact factor: 12.701

Review 10.  Neutrophils as emerging therapeutic targets.

Authors:  Tamás Németh; Markus Sperandio; Attila Mócsai
Journal:  Nat Rev Drug Discov       Date:  2020-01-22       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.